Hit Selection. PeptiDream will be responsible for using Commercially Reasonable Efforts to identify Hits for each Collaboration Target. On an ongoing basis, PeptiDream will disclose to RayzeBio, though the JRC, the sequence of each Hit and its consensus sequence families, homologues or other trends, along with information about synthesis and formulation and any other information reasonably requested by RayzeBio with respect to the Hits. PeptiDream will also provide information about [***] and other characteristics set forth in the Research Plan[***]. RayzeBio will identify which Hits meet the selection criteria for advancement to Conjugate. The JRC will determine which Hits will be conjugated to chelator agents by PeptiDream to generate Conjugates. The Parties will discuss the design of the Conjugate and best practice for conjugating the Hit to a chelator. For a given Hit, the Parties may determine that more than one Conjugate should be evaluated. The Parties may collaboratively design the Conjugates and, in certain situations, may choose to generate more than one Conjugate per Collaboration Target for comparison and optimization of Hits. PeptiDream will promptly use Commercially Reasonable Efforts to generate Conjugates with all Hits selected by the JRC. All rights in any unselected Hits (unless included in Derivatives) will remain with PeptiDream.
Hit Selection. [***]. For each Project the Parties shall agree through the JSC on up to [***] Primary Hits and Primary Hit Series for entering into Phase II (such selected Primary Hits or Primary Hit Series a “Qualified Hit” and structurally related “Qualified Hit Series”, respectively). [***]. If there are no Primary Hits for a Project, as reported to the JSC, the Project shall be discontinued, unless otherwise mutually agreed by the Parties through the JSC. Phase 2 – Initial Qualified Hit Optimization and in-vivo validation of Lead Candidates
